Brief: Genocea Doses First Patient In Phase 1/2A Titan Clinical Trial For Gen-011 Neoantigen-Targeted T Cell Therapy
13/07/2021 12:31
July 13 (Reuters) - Genocea Biosciences Inc GNCA.O :
* GENOCEA DOSES FIRST PATIENT IN PHASE 1/2A TITAN CLINICAL
TRIAL
FOR GEN-011 NEOANTIGEN-TARGETED T CELL THERAPY
Source text for Eikon: ID:nGNX4gNpBT
Further company coverage: GNCA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Genocea Biosciences
See all newsBluebird, Chimerix, Clovis have under 6 months of cash left - Truist
Genocea Biosciences plunges as it winds down operations
Brief: Genocea Announces Wind Down Of Operations And Delisting From Nasdaq
Genocea Biosciences Inc reports results for the quarter ended in March - Earnings Summary
U.S. STOCKS ON THE MOVE-Oppenheimer Holdings, IES Holdings Inc, Avantor Inc